# Fianlimab PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/fianlimab

> The next catalyst for fianlimab, sponsored by REGENERON PHARMACEUTICALS, INC. (REGN), is its topline data readout, Jan to Apr 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | fianlimab |
| Codes | REGN3767 |
| Sponsor | REGENERON PHARMACEUTICALS, INC. (REGN) https://sec-api.dev/companies/regn/catalysts |
| Indications | [Melanoma](https://sec-api.dev/indications/melanoma), [Non-small Cell Lung Cancer](https://sec-api.dev/indications/non-small-cell-lung-cancer), [Resectable Non-small Cell Lung Cancer](https://sec-api.dev/indications/resectable-non-small-cell-lung-cancer), [Advanced Non-Small Cell Lung Cancer](https://sec-api.dev/indications/advanced-non-small-cell-lung-cancer) |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### Apr 2025: interim data readout

- Status: scheduled. Date confidence: month. Stage: 2/3.
- First seen 2025-04-29, last confirmed 2025-04-29.
- SEC Form 10-Q (accession 0001804220-25-000022): "In April 2025, a pre-planned interim analysis was conducted on two ongoing Phase 2/3 studies evaluating the combination of fianlimab and cemiplimab in first-line advanced NSCLC." https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/regn-20250331.htm

### 2H 2025: NDA/BLA submission

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-01-13, last confirmed 2025-01-13.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-002826): "Results from the first Phase 3 study in first-line metastatic melanoma are expected in the second half of 2025, with a potential BLA submission to follow." https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-1.htm

### March 12, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Melanoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05352672 (Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-12 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT05352672

### Aug to Nov 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Resectable Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06161441 (A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-24 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06161441

### August 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 2. Indication: Resectable Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06161441 (A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-24 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06161441

### Jan to Apr 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Melanoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05608291 (A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT05608291

### January 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Melanoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05608291 (A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT05608291

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Melanoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06246916 (A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-22 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06246916

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Melanoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06246916 (A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-22 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06246916

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Advanced Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05785767 (A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT05785767

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Advanced Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05785767 (A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT05785767

### Jan to Apr 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05800015 (A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-01-16 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT05800015

### January 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05800015 (A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-01-16 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT05800015

## Same indication

- [ABP-206](https://sec-api.dev/pdufa/abp-206) (AMGN)
- [Krazati (adagrasib)](https://sec-api.dev/pdufa/adagrasib) (BMY)
- [BNT116](https://sec-api.dev/pdufa/bnt116) (REGN)
- [Brentuximab vedotin](https://sec-api.dev/pdufa/brentuximab-vedotin) (PFE)
- [Calderasib](https://sec-api.dev/pdufa/calderasib) (MRK)
- [Libtayo® (cemiplimab)](https://sec-api.dev/pdufa/cemiplimab) (REGN)
- [Datopotamab deruxtecan](https://sec-api.dev/pdufa/datopotamab-deruxtecan) (AZN)
- [Domvanalimab](https://sec-api.dev/pdufa/domvanalimab) (RCUS)
- [Encorafenib](https://sec-api.dev/pdufa/encorafenib) (PFE)
- [Fianlimab+cemiplimab](https://sec-api.dev/pdufa/fianlimab-cemiplimab) (REGN)
- [LBL-007](https://sec-api.dev/pdufa/lbl-007) (ONC)
- [Opdivo® (nivolumab)](https://sec-api.dev/pdufa/nivolumab) (BMY)
- [Tagrisso® (osimertinib)](https://sec-api.dev/pdufa/osimertinib) (AZN)
- [PF-08634404](https://sec-api.dev/pdufa/pf-08634404) (PFE)
- [Pumitamig](https://sec-api.dev/pdufa/pumitamig) (BMY)
- [RHUPH20](https://sec-api.dev/pdufa/rhuph20) (BMY)
- [KISQALI® (ribociclib)](https://sec-api.dev/pdufa/ribociclib) (NVS)
- [Sacituzumab govitecan-hziy (sg)](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy-sg) (GILD)
- [ORPATHYS® (savolitinib)](https://sec-api.dev/pdufa/savolitinib) (HCM)
- [LUMYKRAS™ (sotorasib)](https://sec-api.dev/pdufa/sotorasib) (AMGN)
- [Telisotuzumab vedotin](https://sec-api.dev/pdufa/telisotuzumab-vedotin) (ABBV)
- [TEVIMBRA® (tislelizumab)](https://sec-api.dev/pdufa/tislelizumab) (ONC)
- [Volrustomig](https://sec-api.dev/pdufa/volrustomig) (AZN)
- [YuTuo (zimberelimab)](https://sec-api.dev/pdufa/zimberelimab) (GILD)

Calendar months: [August 2026](https://sec-api.dev/fda-calendar/2026-08), [January 2027](https://sec-api.dev/fda-calendar/2027-01), [March 2027](https://sec-api.dev/fda-calendar/2027-03), [September 2027](https://sec-api.dev/fda-calendar/2027-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/fianlimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Fianlimab PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/fianlimab

```bibtex
@misc{secapidev_pdufa_fianlimab_20261116,
  title        = {Fianlimab PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/fianlimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_fianlimab_20261116","title":"Fianlimab PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/fianlimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
